The Department of Health and Human Services on Wednesday told the Food and Drug Administration to stop enforcing its compounding rules against six peptides the agency has spent years trying to keep off the market. The instruction arrived in an interim policy posted for public inspection at the Federal Register, and it names BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. The policy applies to state-licensed pharmacies, federal facilities and licensed physicians, and it comes with conditions.
None of the six is approved for any use. The policy does not approve them either. It says HHS will not take action against a compounder that follows its rules. Approval rests on clinical evidence of safety and effectiveness; enforcement discretion rests on a decision not to act. The gap between those two things is the story.
That gap has an institutional shape. The FDA enforces its compounding rules through inspections, warning letters and injunctions. A department statement that it will not act removes the threat that normally gives those tools force without rewriting a single rule. Inspectors can still document a violation. The department that oversees them has said it will not pursue one, which leaves the agency's field staff in an awkward position.
The policy has no signature from the FDA and does not describe the agency's view. It is framed entirely as an HHS document, which is itself unusual. Decisions about what compounding pharmacies may make have sat with the FDA for decades, exercised through a dedicated office and a 503A bulks list that has changed slowly.
The order is not to look
The operative sentence is narrow. HHS does not intend to take action against a state-licensed pharmacy, federal facility or licensed physician that compounds a covered peptide when the policy's requirements are met. It is a statement about enforcement, not a change in the legal status of the substances.
That distinction carries real consequences. A product made under the policy is still a compounded drug, not an approved one. Its label must say so, and the policy requires that label to read: "This is a compounded drug product. Not for resale." The FDA Law Blog describes the arrangement as a conditional pathway, substance by substance and route by route, not a blanket green light.
The policy also lasts only until the FDA finishes rulemaking on each peptide. That is not a short horizon. Six bulk substances have completed the 503A notice-and-comment process in roughly 15 years, according to the same analysis. HHS says it may revisit the policy, in whole or in part, if a safety signal or a product quality problem appears.
States are not bound by it. A state board of pharmacy can still restrict compounding within its jurisdiction, and a state attorney general can still bring a consumer protection case. The policy sets a federal enforcement posture; it does not settle the rules that apply in a given state.
Six substances and a list of conditions
The six peptides are a specific set, not a category. BPC-157 and TB-500 are the injury-repair pair that wellness sellers often market together. Epitalon is sold as a sleep and longevity aid. KPV is pitched as an anti-inflammatory. MOTS-c is marketed for weight and bone health. Semax is sold for migraine and chronic pain. Scientific American lists the same six and notes that most have thin human evidence behind them.
The conditions are where the policy does its work. The bulk peptide must come from a manufacturer registered with the FDA as a drug establishment and compliant with current good manufacturing practice. The manufacturer's physical location must appear on the certificate of analysis. The certificate must characterize the substance and carry testing consistent with the policy's technical appendix, which is more demanding than what compounders have typically relied on. Appendix B fixes the identity of each peptide by amino acid sequence, structure, molecular weight and formula.
Route of administration is limited peptide by peptide. BPC-157 is listed for subcutaneous, intramuscular, oral and topical use. TB-500 and MOTS-c are limited to injection. Epitalon is limited to intermittent injection courses. Semax is intranasal. KPV is topical or oral. The only delivery device that may be co-packaged is a syringe cleared by the FDA through the 510(k) pathway, on the reasoning that more complex devices add risk.
A patient-specific prescription is required. Serious adverse events and product quality problems must go to MedWatch. A single active ingredient per product is the reading the FDA Law Blog gives the text, which would rule out the multi-peptide blends sold online. Scientific American, working from the same announcement, reports that some combinations of peptides made by registered manufacturers are allowed. The discrepancy is unresolved in the public documents, and it matters for the products most often marketed as stacks.
FDA staff lost the argument, then wrote the guardrails
The policy reverses the direction of travel inside the agency. In 2023, the FDA added more than a dozen peptides, including BPC-157 and TB-500, to its list of substances that should not be compounded, citing risks of allergic reactions, kidney damage and tumor growth.
The advisory process then moved the other way. At a meeting on July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding the six peptides to the 503A bulks list. Several votes were close. BPC-157, KPV and TB-500 each passed 8 to 6 with one abstention, according to the meeting record summarized by the FDA Law Blog. FDA staff had recommended against inclusion in briefing documents dated June 29, pointing to limited human data and poorly characterized substances.
Most FDA scientific staff opposed the policy that emerged, and they had limited input in drafting it, according to Associated Press reporting published by The Guardian. The reporting rests on six people familiar with the deliberations who spoke on condition of anonymity. An HHS spokesperson did not immediately respond to a request for comment, the AP said.
The department's authority here is a delegation, not a separate grant. Federal law gives HHS control over drug regulation, and the department has long exercised that control through the FDA. When the two disagree, the department's view prevails. That is how an HHS document can direct enforcement on a question the FDA's own scientists have spent years answering the other way.
FDA staff did supply technical help, and the final text carries their fingerprints: sourcing from registered manufacturers, certificates of analysis, adverse event reporting, identity testing. The agency's scientists lost the argument about whether to open the door. They got to write the door frame.
The gray market the policy says it will shrink
HHS frames the policy as a way to pull demand away from an unregulated market. Peptide sellers often label vials "for research use only" because the FDA does not regulate research chemicals. Many buyers order from chemical manufacturers based in China and inject the material without a prescription or a pharmacist's involvement.
The scale is not small. ASOP Global, a consumer protection group that opposes the policy, counted about 21,000 online peptide listings across 330 websites before the announcement, including 8,807 for BPC-157 and 2,645 for TB-500. Those figures come from an advocacy source and describe listings, not sales, but they sketch the market the policy is trying to redirect.
The financial reaction was immediate. Shares of Hims & Hers rose about 6 percent after the announcement, according to Yahoo Finance, a sign that investors read the policy as an opening for telehealth compounders. The company has said it is waiting for final rulemaking.
Kennedy has made no secret of his own use. He has called himself a big fan of peptides and said he used BPC-157 for a muscle injury. That personal endorsement sits behind a policy that his department wrote over the objections of the scientists who review these substances for a living.
Compounding has a history regulators remember
The policy lands in an industry with a safety record that shaped the current rules. In 2012, contaminated injections from a Massachusetts compounding pharmacy caused a fungal meningitis outbreak that killed dozens of people and sickened hundreds more. The outbreak led to the Drug Quality and Security Act and a stronger separation between traditional 503A compounding and the larger 503B outsourcing facilities.
The FDA has stayed active on the peptide side. In August it sent warning letters to online vendors selling peptides labeled for research use, arguing that bacteriostatic water and dosing calculators showed the products were meant for human use. A September warning letter raised similar concerns about compounded GLP-1 products. The agency also tracked a glutathione contamination outbreak that sickened more than 20 people across at least four states.
Medical groups are not persuaded. Willie Underwood III, president of the American Medical Association, said the peptides have "not undergone the rigorous testing required of FDA-approved drugs." He added that allowing pharmacies to compound unapproved synthetic peptides without sufficient evidence puts patients at risk. The AMA's objection is about evidence, not access: it does not argue that patients should be unable to obtain the drugs, but that a prescription should follow a review the FDA has not completed.
The final rule is where this gets decided
The policy is a bridge, and bridges get tested. The 503A bulks list is amended through notice-and-comment rulemaking, which means each peptide must clear a proposal, a comment period and a final rule before its status is settled. Until then, the enforcement discretion can be withdrawn. The policy says HHS may revisit it if safety or quality problems emerge.
Legal exposure runs in two directions. Trade groups have argued that the FDA cannot authorize compounding through an interim policy while rulemaking is pending, because the statute assigns that decision to the formal process. If a challenge succeeds, the pathway closes. If a state refuses to follow the federal posture, a pharmacy could comply with HHS and still face a state action.
For patients, the practical result is that six substances move from the gray market into a pharmacy with a prescription, a certificate of analysis and a reporting channel. That is a real change in supply. It is not a change in evidence. A certificate of analysis speaks to identity, purity and manufacturing, not to whether a peptide does what a seller says it does, and a prescription is not a finding that the substance has been shown to help. The trials that would answer whether these peptides work, and at what dose and route, have not been run. The policy makes them easier to buy before anyone has finished asking whether they help.
Primary sources
- Department of Health and Human Services, interim enforcement discretion policy for six peptide bulk drug substances, posted for public inspection October 28, 2026. Federal Register
- Department of Health and Human Services, Appendix B, peptide identities and routes of administration. hhs.gov
- Associated Press, report on FDA scientists' opposition to the peptide policy, published by The Guardian on October 28, 2026. theguardian.com
- Scientific American, report on the six peptides and the American Medical Association's response, October 28, 2026. scientificamerican.com
- FDA Law Blog, analysis of the interim policy's conditions and the July advisory committee votes, October 28, 2026. thefdalawblog.com
- Yahoo Finance, report on the market reaction, October 28, 2026. finance.yahoo.com